Yongxian Zhuang, is a research scientist with PhD, MD, and DABCP and a passion for leading therapeutic pharmacological advancements in oncology.

Before joining full time Rubedo Life Sciences, she worked at the Mayo Clinic, Department of Molecular Pharmacology & Experimental Therapeutics. Her background includes more than 10 years of project management and extensive translational research experience in method development for new drug discovery and biomarker identification, resulting in nine publications and two Phase I/II clinical trials. She has several years of field-based medical experience in USA and China.

Yongxian, is certified by the American Board of Clinical Pharmacology and has completed an NIH-T32 Clinical Pharmacology fellowship in pharmacogenomics at Mayo Clinic and focused on drug biomarker identification for personalized therapy, novel drug discovery through high-throughput drug screening and proteomics signalling pathway identification. She developed novel methods for establishing preclinical mouse models and primary cancer cell lines as well and she is leading authors on several scientific publications in high impact journals in the field (such as the Journal of Clinical Investigation, EMBO Reports and Molecular Cancer Research).

​

Prior to that, she worked at the Sanford Research Cancer Center in South Dakota.